{"schema_version":"secwatch.filing_event.v1","accession":"0001599901-24-000071","form_type":"8-K","ticker":null,"cik":"0001599901","company_name":"Avidity Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.160052+00:00","generated_at":"2026-06-02T06:03:37.982390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avidity Q1 cash $915.9M, Phase 3 HARBOR trial on track, positive long-term DM1 data","bullets":["Cash position $915.9M at Q1 end after $400M private placement; funding into late 2026.","Phase 3 HARBOR trial for del-desiran in DM1 to initiate Q2 2024; FDA Breakthrough Therapy designation.","Long-term MARINA-OLE data showed reversal of DM1 progression on vHOT, muscle strength, daily activities.","R&D expenses $66.8M (up 40% YoY); collaboration revenue $3.5M (up 59% YoY).","Upcoming: FSHD FORTITUDE preliminary data Q2 2024, DMD EXPLORE44 5 mg/kg data 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001599901-24-000071","json":"https://secwatch.observer/filing/0001599901-24-000071.json","markdown":"https://secwatch.observer/filing/0001599901-24-000071.md","text":"https://secwatch.observer/filing/0001599901-24-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/0001599901-24-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/rna-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:03:37.982390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70f3ee286421ff670f39cc698ad6b3ae9c5c2d6d","claim":"Avidity Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Avidity Biosciences, Inc. issued a press release announcing its financial results for the quarter and year ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/0001599901-24-000071-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}